Efficacy and safety of Impella 5.0 in cardiogenic shock: an updated systematic review
| Autor: | Claudia Marini, Federico Pappalardo, Letizia Bertoldi, Eleonora Bossi, Anna Odone, Davide Alessio, Luca Diamanti, Giovanni Gaetti |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Protocol (science)
medicine.medical_specialty business.industry Cardiogenic shock Shock Cardiogenic Comparative safety Retrospective cohort study medicine.disease Cardiac support law.invention Treatment Outcome Randomized controlled trial law Emergency medicine Molecular Medicine Medicine Humans Multicenter Studies as Topic Heart-Assist Devices Prospective Studies Registries Cardiology and Cardiovascular Medicine business Impella Retrospective Studies |
| Zdroj: | Future cardiology. 18(3) |
| ISSN: | 1744-8298 |
| Popis: | Aim: The impact on safety and efficacy outcomes of Impella 5.0 in cardiogenic shock (CS) has not been systematically assessed. Materials & methods: We conducted a systematic review of the literature (PROSPERO protocol: CRD42020164680) to critically appraise available evidence on Impella 5.0 comparative safety, efficacy and effectiveness. Results: Of 244 retrieved citations, 17 original articles met the a priori defined inclusion criteria. All included studies had a retrospective study design and, overall, reported on, respectively, 52 and 67 different safety and efficacy/effectiveness outcomes. Thirty-day survival rates ranged from 40 to 94%, myocardial recovery from 18 to 93%. Conclusion: Impella 5.0 provides a full cardiac support, it is associated with a lower rate of vascular complications, it represents a valuable bridge-to-decision and allows for resolution of intercurrent clinical conditions. As available data suggest Impella 5.0 good performance in CS of various etiologies, more solid evidence will come from much-needed large-scale all-comer registries and prospective multicenter randomized trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|